This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Nektar Therapeutics today announced the start of its Phase 2 clinical development program to evaluate NKTR-102 (PEG-irinotecan) as a potential treatment for colorectal cancer. NKTR- 102 is Nektar's lead oncolytic candidate using the company's innovative small molecule PEGylation technology platform.
We care about your feedback. Let us know how we can improve your CancerCompass experience.